BidaskClub upgraded shares of Natera (NASDAQ:NTRA) from a hold rating to a buy rating in a report issued on Saturday.
Several other analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Natera from a sell rating to a hold rating in a research report on Friday, June 8th. ValuEngine raised shares of Natera from a hold rating to a buy rating in a research report on Wednesday, June 6th. Morgan Stanley lifted their price target on shares of Natera from $15.00 to $16.00 and gave the company an overweight rating in a research report on Wednesday, May 9th. Finally, Craig Hallum began coverage on shares of Natera in a research report on Monday, April 9th. They issued a buy rating and a $16.00 price target for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Natera presently has an average rating of Buy and a consensus price target of $14.80.
Natera opened at $14.61 on Friday, according to Marketbeat Ratings. Natera has a 12-month low of $7.78 and a 12-month high of $14.99. The company has a debt-to-equity ratio of -18.90, a current ratio of 1.80 and a quick ratio of 1.68. The firm has a market capitalization of $776.80 million, a P/E ratio of -6.09 and a beta of 2.07.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, May 8th. The medical research company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Natera had a negative net margin of 58.84% and a negative return on equity of 752.93%. The business had revenue of $62.34 million during the quarter, compared to analyst estimates of $54.86 million. During the same period in the previous year, the business posted ($0.70) EPS. The business’s revenue for the quarter was up 26.2% compared to the same quarter last year. sell-side analysts expect that Natera will post -2.05 earnings per share for the current year.
In other Natera news, major shareholder Claremont Creek Partners Fund sold 25,027 shares of Natera stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $11.59, for a total transaction of $290,062.93. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 67,374 shares of company stock worth $770,360 over the last ninety days. Insiders own 13.18% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. Sofinnova Ventures Inc purchased a new position in Natera during the 1st quarter worth $28,742,000. Millennium Management LLC boosted its holdings in Natera by 218.7% during the 1st quarter. Millennium Management LLC now owns 316,222 shares of the medical research company’s stock worth $2,931,000 after acquiring an additional 216,987 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in Natera by 11.8% during the 4th quarter. Macquarie Group Ltd. now owns 1,494,152 shares of the medical research company’s stock worth $13,432,000 after acquiring an additional 157,159 shares during the last quarter. Asymmetry Capital Management L.P. boosted its holdings in Natera by 62.9% during the 1st quarter. Asymmetry Capital Management L.P. now owns 325,529 shares of the medical research company’s stock worth $3,018,000 after acquiring an additional 125,752 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its holdings in Natera by 15.0% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 585,426 shares of the medical research company’s stock worth $5,427,000 after acquiring an additional 76,545 shares during the last quarter. 69.44% of the stock is currently owned by hedge funds and other institutional investors.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.